Quest Diagnostics

What Quest Diagnostics does

Quest Diagnostics Incorporated is a publicly traded clinical laboratory company (NYSE: DGX) founded in 1967 and headquartered in Secaucus, New Jersey. It operates 2,000+ Patient Service Centers across the United States and serves approximately half of U.S. physicians and hospitals and roughly one-third of American adults each year, processing more than 200 million tests annually through its 3,500+ test menu spanning routine, esoteric, and genetic diagnostics. The company maintains wholly owned subsidiaries including Haystack Oncology (molecular/MRD testing, acquired 2023 for $300 million), LifeLabs (Canadian community lab network, acquired August 2024), Cleveland HeartLab (cardiometabolic Center of Excellence), and Quest Consumer Inc. (direct-to-consumer storefront).

The company generates revenue across seven primary streams: insurance-billed diagnostic testing services (Q1 2026 revenue of $2.90 billion, up 9.2% YoY), direct-to-consumer testing via questhealth.com (150+ self-pay tests with PWNHealth clinical oversight), health plan/insurance reimbursement across major U.S. payers, employer drug screening and workforce health, life sciences and pharma services (with 650+ thought leaders supporting clinical trials), Quest Mobile in-home phlebotomy ($79 flat fee per visit, not insurance-billed), and consumer health integrations (WHOOP Specialized Panels at $299 per panel, plus Superpower Health, INVIAH). The technology stack includes the Quanum Lab Services Manager cloud platform, Clinical Insights Companion longitudinal analytics, MyQuest patient portal, Quest AI Companion generative AI tool, and a FHIR API integrated with Apple Health. Notable proprietary tests include Haystack MRD ctDNA liquid biopsy (FDA Breakthrough Device Designation 2025, all 50 states authorized June 2026), Cardio IQ advanced lipid testing, ImmunoCAP IgE allergy, Quest AD-Detect Amyloid Beta 42/40 for Alzheimer's, LeukoVantage myeloid panels, and ANAlyzeR autoimmune panels.

Name

Quest Diagnostics

Legal name

Quest Diagnostics Incorporated

Website

https://questdiagnostics.com

Company type

Public

Founded year

1967

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Quest Diagnostics is a publicly traded clinical laboratory company operating 2,000+ Patient Service Centers and offering 3,500+ diagnostic tests, serving approximately half of U.S. physicians and hospitals and one-third of American adults annually through insurance billing, direct-to-consumer sales, and life sciences partnerships.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Diagnostic Testing Services

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Clinical laboratory services
• Diagnostic testing
• Esoteric genetic testing
• Workplace drug screening
• Biopharma lab services

Headquarters

HQ city

Secaucus

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Testing Services (B2B): Primary revenue stream from clinical laboratory testing services (blood tests, body fluid testing, tissue pathology, cytology, genetic testing, drug screening) ordered by physicians and billed to insurance or health plans. Q1 2026 revenue: $2.90 billion, 9.2% YoY growth, with 10.9% requisition volume growth. Requisitions processed at 2,000+ Patient Service Centers.
2. Direct-to-Consumer Testing (questhealth.com): Self-pay revenue from patients purchasing tests online without a doctor's visit. 150+ lab tests available for direct purchase through questhealth.com, with online results delivery and optional physician consultation. Licensed professionals from PWNHealth LLC provide clinical oversight.
3. Health Plan & Insurance Reimbursement: Revenue from in-network laboratory services billed through major U.S. health plans including UnitedHealthcare, Aetna, Humana, Cigna, and most Anthem and BlueCross BlueShield plans. Quest participates in UnitedHealthcare Preferred Lab Network offering $0 out-of-pocket for members.
4. Employer Drug Screening & Workforce Health: Revenue from employer drug screening, international drug testing, biometric screening, and lab spend management services, plus employer population health solutions. Includes both urine and oral fluid drug testing.
5. Life Sciences / Pharma Services: Revenue from pharma, biotech, CRO, MedTech, and academic clients via Discovery (650+ medical/scientific/regulatory thought leaders), Clinical Trials (comprehensive test menu and assay development lab services), and Commercialization (co-developed biomarker education, de-identified alerts on biomarker populations). Also includes real-world laboratory database services for clinical trial recruitment.
6. Quest Mobile® In-Home Sample Collection: Direct-pay revenue from patients using in-home phlebotomy service at $79 per in-home collection fee. Operates as a separate services division that does not bill insurance, Medicare, Medicaid, or commercial plans.
7. Consumer Health Integrations (WHOOP, etc.): Revenue from powering consumer health platforms such as WHOOP Advanced Labs and Specialized Panels ($299 per panel), Superpower Health, Function Health, INVIAH, and Oura. Provides exclusive laboratory testing infrastructure for third-party consumer health brands.

Pricing tiers

Go-to-market motion1 record

Distribution channels10 records

Marketing channels8 records

Core offering

Quest Diagnostics is a clinical laboratory that performs routine, esoteric, and genetic diagnostic testing across 20+ medical specialties through a national network of 2,000+ Patient Service Centers and complementary digital platforms. The company sells these services to physicians and hospitals, employers (drug screening, workforce health), health plans, and biopharma clients, and increasingly direct-to-consumer via QuestHealth.com and Quest Mobile in-home phlebotomy. Its proprietary technology platforms Quanum Lab Services Manager, MyQuest, Quest AI Companion, and specialty tests such as Haystack MRD ctDNA liquid biopsy and Quest AD-Detect Amyloid Beta 42/40 differentiate the offering.

Product overview

Quest Diagnostics operates an integrated diagnostic information services platform centered on its national network of more than 2,000 Patient Service Centers, 3,500+ lab tests, and complementary digital and consumer products. The core platform for healthcare professionals is Quanum Lab Services Manager (with Quanum eLabs/EHR and the Clinical Insights Companion), which clinicians use to order tests, view results, and surface longitudinal insights. Patients interact via the MyQuest portal and the QuestHealth.com direct-to-consumer storefront, while Quest Mobile extends collection into the home. Specialty testing brands include Cardio IQ and the 4myheart program (Cleveland HeartLab), the Haystack MRD liquid biopsy assay from acquired subsidiary Haystack Oncology, the ImmunoCAP IgE allergy portfolio, the Kidney Profile and Cystatin C with eGFR panels, the ELF Score for liver disease, ANAlyzeR autoimmune panels, the Quest AD-Detect Amyloid Beta 42/40 Alzheimer's test, and prognostic oncology tests such as MelaNodal Predict and LeukoVantage. Supporting these are operational tools including Easy Pay billing, workforce drug screening, employer population health, life-sciences biopharma services, and the new Quest AI Companion that applies generative AI to help patients interpret lab results.

Differentiator

Problem solved

Functional benefit

Brands

• MyQuest: Free online patient portal and mobile app for accessing test results, scheduling appointments, tracking health history, and managing family/caregiver health information via the My Circle feature
• Quanum
• Haystack MRD
• Cleveland HeartLab
• Cardio IQ
• 4myheart
• Quest Mobile
• ImmunoCAP
• LeukoVantage
• MelaNodal Predict
• ANAlyzeR
• Quest AI Companion
• Quest Pharma Solutions
• Quest Diagnostics Nichols Institute

Products and services

• MyQuest Free and secure patient portal from Quest Diagnostics that lets patients view test results, schedule and manage appointments, track health history, share results with doctors, and access family test results via the My Circle feature. Available as iOS and Android mobile apps.
• QuestHealth.com (Quest Direct) Direct-to-consumer online platform where patients can shop for and purchase over 150 lab tests without a doctor's visit, with clinical oversight provided by PWNHealth LLC. Results are delivered with the option to consult a healthcare provider.
• Quanum Lab Services Manager Cloud-based online business tool for physicians, hospital, and office staff to order lab tests for patients, view patient lab test results, order supplies, and access Lab Utilization Reports. Includes Quest Lab Alert for Physicians real-time Priority and STAT results.
• Clinical Insights Companion Longitudinal lab-data analytics tool that surfaces trends across time and conditions, assists in identifying care gaps and emerging clinical patterns, and consolidates lab history from multiple sources in one unified view to support informed clinical decisions and follow-ups.
• Quest Mobile Mobile phlebotomy service offering in-home sample collection by Quest Mobile phlebotomists. Operates as a separate services division from Quest Diagnostics Incorporated with a $79 in-home collection fee not billed to insurance.
• Haystack MRD Ultrasensitive circulating tumor DNA (ctDNA) liquid biopsy test from Haystack Oncology (Quest's wholly owned subsidiary) that detects residual or recurring disease in patients with solid tumor cancers. FDA Breakthrough Device Designation for Stage II colorectal cancer. Authorized for patient testing in all 50 U.S. states as of June 2026.
• Quest AD-Detect Amyloid Beta 42/40 Blood-based biomarker test to help identify patients who are candidates for early antibody treatment for Alzheimer's disease by measuring amyloid beta 42/40 ratio.
• ImmunoCAP IgE Blood Allergy Tests Comprehensive range of IgE blood allergy tests covering regional environmental allergens, food allergens and components, insect and venom allergens, biologics and occupational allergens, and animal allergens. Includes Allergen Component Testing (ACT) and 18 regional allergy profiles.
• Cardio IQ Advanced cardiovascular risk assessment reporting from the Quest Cardiometabolic Center of Excellence at Cleveland HeartLab. Provides color-coded progressive risk values, functional category grouping, and inclusive history of prior Cardio IQ reports covering lipid subclass characterization, inflammation, metabolic, and genetic testing.
• 4myheart Program Clinical educator-led program that uses cardiovascular test results to customize patient education about nutrition, exercise, stress management, and therapy adherence, pursuant to each clinician's treatment plan.
• ELF Score Test used to determine which patients are at risk for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
• Kidney Profile Combined test panel that includes both eGFR blood test and urine albumin-to-creatinine ratio (uACR) test to assess kidney function and damage for early CKD detection, aligned with National Kidney Foundation guidelines.
• MelaNodal Predict Molecular prognostic test used to evaluate prognosis in melanoma patients.
• LeukoVantage Myeloid Neoplasm Panels Molecular testing panels for evaluating prognosis in myeloid neoplasms including hematologic cancers.
• ANAlyzeR Autoimmune Panel ANA IFA panel with reflex to titer, pattern, and reflex multiplex 11 antibody cascade for diagnosing overlapping autoimmune diseases including systemic autoimmune panel 1.
• Quest AI Companion AI-powered companion tool that helps patients gain a clearer understanding of their lab test results through personalized natural-language insights and explanations.
• Easy Pay Patient payment program that authorizes an estimated out-of-pocket amount on a credit, debit, or health savings card at the time of visit. The card is only charged if there is a remaining patient balance after insurance is billed.
• Quest Drug Screening Solutions Workplace drug and alcohol screening solutions including urine and oral fluid drug testing, international drug testing, and lab spend management for employers across safety-sensitive industries.
• Quest HPV Self-Collection Service Quest Diagnostics HPV self-collection service enabling patients to self-collect samples for HPV testing.
• Quest STI Vaginal Self-Collection STI vaginal self-collection service offering patients a simple, quick, and convenient way to gather a vaginal sample discreetly for STI testing.
• WHOOP Specialized Panels (powered by Quest Diagnostics) WHOOP Specialized Panels powered exclusively by Quest Diagnostics in the United States. Targeted blood biomarker tests priced at $299 per panel analyzing 75-89 biomarkers across Heart Health, Performance, Metabolic Health, Women's Health, and Men's Health categories. Integrates Quest-collected biomarker data with WHOOP's continuous wearable sensor data to deliver personalized health insights through the WHOOP app.

Named customers17 records

Segments8 records

Ideal customer profiles7 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability9 records

Feature14 records

Partnerships

23 partnerships are on record, tiered major, flagship, minor and moderate.

• Hackensack Meridian Center for Discovery and Innovation (CDI)majorStrategic or Co-development Partner · 18 June 2026Researchers from Hackensack Meridian CDI and Quest Diagnostics co-published a peer-reviewed study in Nature Communications on Klebsiella pneumoniae, screening 2,000+ samples from 42 U.S. states. Found 100% of bacteria were multidrug-resistant with CTX-M-15 gene as main driver of resistance spread.
• Axtria Inc.flagshipStrategic or Co-development Partner · 10 June 2026Quest Diagnostics has a 15-year partnership with Axtria recognized with a Bedrock Honor at Axtria Ignite 2026 (June 10-11, Princeton NJ). Axtria's Ignite Leadership Awards recognized transformation leaders from Bristol Myers Squibb, GSK, and Biogen. The partnership reflects deep collaboration in life sciences data and AI capabilities.
• Bristol Myers SquibbminorStrategic or Co-development Partner · 10 June 2026Bristol Myers Squibb recognized with Ignite Leadership Award at Axtria Ignite 2026 alongside Quest Diagnostics' Bedrock Honor for 15-year partnership with Axtria. Suggests broader ecosystem alignment among transformation leaders in life sciences data and AI.
• Superpower HealthminorOEM/ Whitelabel/ Licensing Partner · 31 May 2026Superpower Health offers blood tests through a partnership with Quest Diagnostics as a more affordable alternative to competitors like Function Health. AI-powered health testing service for consumers.
• AdenocytemoderateStrategic or Co-development Partner · 26 May 2026Adenocyte established a collaboration with Quest Diagnostics for national laboratory services to support commercial expansion of LINFU pancreatic cancer early detection platform through 2026.
• PricewaterhouseCoopers LLPminorImplementation/ SI/ Consulting Partner · 21 May 2026Quest Diagnostics shareholders ratified PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for 2026 at the 2026 Annual Meeting.
• Health Information Sharing and Analysis Center (Health-ISAC)moderateStrategic or Co-development Partner · 21 May 2026Health-ISAC, in partnership with Quest Diagnostics, issued a threat bulletin on Claude Mythos autonomous AI cybersecurity capabilities. Warned that these tools are projected to proliferate globally by late 2026, significantly lowering the barrier for sophisticated cyberattacks against critical infrastructure including healthcare.
• Guardant HealthmajorStrategic or Co-development Partner · 15 May 2026Strategic partnership supporting Guardant's MRD (Minimal Residual Disease) and screening businesses including the Shield blood-based colorectal cancer screening test. Quest's product upgrades and expanded reimbursement coverage with Guardant positioning both on a clearer path to profitability.
• A&O ShearmanminorImplementation/ SI/ Consulting Partner · 13 May 2026A&O Shearman represented Quest Diagnostics in its registered offering of $500 million aggregate principal amount of 5.000% senior notes due 2036. Legal team included partners Erika Kent and Lona Nallengara in New York.
• INVIAHminorOEM/ Whitelabel/ Licensing Partner · 7 May 2026Partnership with INVIAH (AI-native physician home-visit platform launched in Chicago) providing Quest Diagnostics lab draws for in-home physician visits. Beta has completed 20 physician home visits across select North Shore communities.
• Fresenius Medical CareflagshipStrategic or Co-development Partner · 21 April 2026Health system collaboration that contributed approximately 7% of Quest's 10.9% Q1 2026 organic requisition volume growth. Partnership supports clinical innovations and end-stage renal disease services. Called out as key growth driver in Q1 2026 earnings call.
• Corewell HealthflagshipStrategic or Co-development Partner · 21 April 2026Health system collaboration that contributed approximately 7% of Quest's 10.9% Q1 2026 organic requisition volume growth. Called out as a key driver of double-digit volume growth in Q1 2026 earnings call.
• Qiagen N.V.majorTechnology or Integration · 18 April 2026Partnership supporting Qiagen's sample-to-insight workflows, consumables, instruments, and bioinformatics software. Proprietary intellectual property in purification technology and installed instrument base generating consumable lock-in for Qiagen with Quest as customer.
• City of HopeflagshipStrategic or Co-development Partner · 16 April 2026Multi-year research collaboration using Haystack MRD ctDNA test in clinical trials of approximately 500 solid-tumor cancer patients across 14 City of Hope sites in major U.S. metropolitan areas. Covers breast, colorectal, ovarian, and prostate cancer; evaluates whether the test can detect MRD, monitor treatment response, and identify recurrence earlier than imaging.
• WHOOPflagshipOEM/ Whitelabel/ Licensing Partner · 16 April 2026WHOOP Specialized Panels powered exclusively by Quest Diagnostics in the United States at $299 per panel analyzing 75-89 biomarkers across 5 health categories (Heart Health, Performance, Metabolic Health, Women's Health, Men's Health). Builds on Advanced Labs partnership launched 2025. Also announced Boston Red Sox sponsorship (2026-2028).
• CDC (Increasing Community Access to Testing, Treatment, and Response Program)majorGTM or Marketing Partner · 15 April 2026Quest participated in the CDC's Increasing Community Access to Testing, Treatment, and Response (ICATT) program during the COVID-19 pandemic, providing free testing through retail pharmacies via public-private partnerships with CVS, Walgreens, Walmart, and Rite Aid. Model referenced as future public health emergency response template.
• University HospitalsmajorChannel Partner/ Reseller/ Distributor · 1 January 2025Quest acquired the Outreach Lab Services unit of University Hospitals in January 2025, expanding its diagnostic test menu and patient access network in Ohio.
• OhioHealthmajorChannel Partner/ Reseller/ Distributor · 16 October 2024Quest completed acquisition of OhioHealth outreach laboratory assets in October 2024. Morrow County, Ohio outreach lab services transitioning to Quest on August 2, 2026 as part of broader system-wide transition began 18 months earlier. OhioHealth continues inpatient lab services and specialized tests.
• LifeLabsflagshipStrategic or Co-development Partner · 1 August 2024Quest completed acquisition of LifeLabs in August 2024 combining advanced laboratory services with LifeLabs' community laboratory network across Canada. Funded via $1.85B senior notes offering. Plans to transition reference laboratory tests to U.S. facilities in three phases beginning April 6, 2026. Reduced staffing at Sudbury facility by half and cancelled afternoon hours at Kenora lab.
• Haystack OncologyflagshipStrategic or Co-development Partner · 27 April 2023Quest acquired Haystack Oncology for $300 million in cash (2023) to develop new clinical lab services for cancer detection using circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing. Haystack's technology focuses on colorectal, breast, and lung cancers initially. Resulted in development of Haystack MRD test with FDA Breakthrough Device Designation in 2025.
• Summa Health (LabCare Plus)majorChannel Partner/ Reseller/ Distributor · 28 November 2022Quest completed acquisition of Summa Health's outreach laboratory services business LabCare Plus in Northeastern Ohio (Q4 2022). Laboratories in Twinsburg and Pittsburgh providing testing services. All-cash transaction.
• LabTech DiagnosticsmoderateChannel Partner/ Reseller/ Distributor · 14 December 2021Quest acquired substantially all assets of Labtech Diagnostics (December 2021), a clinical laboratory provider operating in South/North Carolina, Georgia, and Florida. Acquisition established a new laboratory in South Carolina supporting regional growth strategy.
• MercymajorChannel Partner/ Reseller/ Distributor · 1 June 2021Quest completed acquisition of Mercy's outreach laboratory services business in all-cash deal (June 2021). Enhances Quest's reach to providers and patients in Arkansas, Kansas, Missouri, and Oklahoma. Mercy continues operating hospital laboratories for inpatient and outpatient care.

Scale indicators28 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Laboratory Corporation of America (Labcorp): Labcorp is Quest's largest direct competitor in U.S. clinical laboratory services, operating a comparable national Patient Service Center network and offering routine, esoteric, and genetic testing with similar payer relationships. The two companies are the dominant duopoly in U.S. clinical lab services and compete head-to-head on physician contracts, hospital outreach, and DTC offerings.
• BioReference Health (OPKO Health): BioReference Health, a subsidiary of OPKO Health, is a U.S. clinical laboratory offering routine, esoteric, and women's health testing with national reach. It is a direct peer in physician-office lab services, specialty diagnostics, and health system outreach.

Broad incumbents

• Sonic Healthcare: Sonic Healthcare is a global diagnostics platform with significant U.S. presence (via Sonic Healthcare USA, including the former Sonic Reference Laboratory and CPL/Austin Pathology) competing in routine and esoteric clinical laboratory services. It is a broad incumbent whose scale and geographic footprint are comparable to Quest in several U.S. markets.
• Eurofins Scientific: Eurofins Scientific is a global laboratory testing services group operating across clinical diagnostics, pharma services, and specialty testing. While its primary scale is in Europe and bioanalytical services, its U.S. clinical and specialty diagnostics business competes with Quest on advanced/esoteric testing menus.

Emerging players

• Guardant Health: Guardant Health is a precision oncology company offering blood-based liquid biopsy tests for therapy selection (Guardant360), MRD, and CRC screening (Shield). Quest has a strategic partnership with Guardant and competes with it in advanced oncology/MRD testing — a core growth franchise anchored by Haystack MRD.
• Natera: Natera is a molecular diagnostics company specializing in cell-free DNA testing including Signatera (tumor-informed MRD), Empower (hereditary cancer), and Vistara (single-gene NIPT). It is a primary emerging competitor in the oncology MRD space where Quest's Haystack MRD is positioned.
• Exact Sciences: Exact Sciences is a molecular diagnostics leader with Cologuard (stool-based CRC screening), Oncotype DX (breast cancer recurrence), and a broader oncology pipeline. It competes with Quest in advanced cancer diagnostics and colorectal cancer screening, areas where Quest is investing via Haystack MRD and Shield partnership.
• Veracyte: Veracyte is a genomic diagnostics company focused on urologic, thyroid, breast, and pulmonary cancers with Afirma, Decipher Prostate, and Percepta. It is an emerging peer in specialty oncology molecular testing where Quest has launched multiple oncology assays.
• Myriad Genetics: Myriad Genetics offers hereditary cancer testing (BRACAnalysis), pharmacogenomics (GeneSight), and prenatal screening. It competes with Quest's hereditary cancer and women's health testing menus in selected specialty segments.
• NeoGenomics: NeoGenomics is a specialty oncology laboratory providing comprehensive cancer testing including solid tumor profiling, hematologic malignancy testing, and clinical trial services. It competes with Quest in oncology/esoteric molecular testing and biopharma services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/QuestDX
• YouTubequestdiagnostics.com/social-media
• Facebookfacebook.com/questdiagnostics
• LinkedInquestdiagnostics.com/social-media
• Instagramquestdiagnostics.com/social-media

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A34 records

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quest Diagnostics